ALLIANCE A081105- Randomized Double Blind Placebo Controlled Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (Egfr) Mutant Non-Small Cell Lung Cancer (NSCLC)

Randomized Double Blind Placebo Controlled Study Of Erlotinib Or Placebo In Patients With Completely Resected Epidermal Growth Factor Receptor (Egfr) Mutant Non-Small Cell Lung Cancer (NSCLC)

ALLIANCE A081105
Cancer
Mehul Patel, MD
Enrolling
Denise Maracle, RN
(585) 747-4555
(585) 922 - 9146